Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.31 |
| ▸ | TUBB | P07437 | 1/20 | 0.31 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.31 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.31 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.31 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.31 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.31 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.31 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.31 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30788168 | 1.00 | MAPT (0.49) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL27153849 | 0.92 | MAPT (0.43) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL29953840 | 0.82 | MAPK8 (0.33) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL29955940 | 0.79 | ENPP2 (0.36) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL20605929 | 0.79 | PIK3CA (0.37) | MAPTCASP1PIK3CAENPP2CA1 | |
| SCHEMBL24354976 | 0.79 | ENPP2 (0.36) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL3635036 | 0.79 | ENPP2 (0.36) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL117586 | 0.78 | PIK3CA (0.38) | MAPTPIK3CAENPP2CA1CA2 | |
| SCHEMBL29956434 | 0.78 | PIK3CA (0.38) | MAPTPIK3CAENPP2CA1CA2 | |
| SCHEMBL1811195 | 0.78 | ENPP2 (0.40) | MAPTCASP1PIK3CAENPP2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114436952-A | Synthesis method of 2-methoxy-3-amino-5-pyridine boronic acid pinacol ester and intermediate thereof | 杭州珠联医药科技有限公司 | 2022-05-06 | — | — | CN | claimed |
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-01-23 | — | — | US | disclosed |
| EP-4423081-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | The Children's Medical Center Corporation (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118201920-A | PAPD5 inhibitors and methods of use thereof | 儿童医疗中心公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023086220-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086220-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-3912978-B1 | PREPARATION METHOD FOR MORPHOLINQUINAZOLINE COMPOUND AND MIDBODY THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2023-02-15 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114436952-A | Synthesis method of 2-methoxy-3-amino-5-pyridine boronic acid pinacol ester and intermediate thereof | 杭州珠联医药科技有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-20220127248-A1 | PREPARATION METHOD FOR MORPHOLINQUINAZOLINE COMPOUND AND MIDBODY THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2022-04-28 | — | — | US | disclosed |
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | PIRAMAL ENTERPRISES LIMITED` (IN) | 2013-11-21 | — | — | US | disclosed |
| CN-103402520-A | Substituted imidazoquinoline derivatives | PIRAMAL LIFE SCIENCES LTD | 2013-11-20 | — | — | CN | disclosed |
| EP-2648733-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | Piramal Enterprises Limited (IN) | 2013-10-16 | — | — | EP | disclosed |
| EP-2593450-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-22 | — | — | EP | disclosed |
| CN-103108873-A | Substituted imidazoquinoline derivatives as kinase inhibitors | PIRAMAL LIFE SCIENCES LTD | 2013-05-15 | — | — | CN | disclosed |
| US-20130116248-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-09 | — | — | US | disclosed |
| WO-2012077031-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011121317-A9 | IMIDAZOTHIADIAZOLES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012007926-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011121317-A1 | IMIDAZO [2,1-B] [1,3,4] THIADIAZOLES AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116248-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK4, MAP3K1 | MAPT 3451/4885CASP1 1740/4885AURKA 209/4885 |
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | FLT4, CDK4, CDK2 | MAPT 3612/4885CASP1 1140/4885AURKA 561/4885 |
| US-20220127248-A1 | PREPARATION METHOD FOR MORPHOLINQUINAZOLINE COMPOUND AND MIDBODY THEREOF | MDK, MYLK4, MYL4 | MAPT 3194/4885CASP1 2572/4885AURKA 620/4885 |
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, PARP15, TERT | MAPT 1601/4885CASP1 3291/4885AURKA 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.